Here you can find the abstracts of biobank research projects in year 2016, which use the samples from Auria Biobank.
Biobank research projects each year:
Maria Gardberg, TYKS-SAPA Patologia
Rintasyöpä on Suomessa naisten tavallisin pahanlaatuinen kasvain. Taudinmäärityksen yhteydessä rintasyöpänäytteestä selvitetään rintasyövän tarkempi tyyppi, jonka perusteella voidaan arvioida taudin ennustetta ja suunnitella tehokas hoito. Suurin osa rintasyövän sairastaneista paranee pysyvästi leikkauksen ja mahdollisten liitännäishoitojen ansiosta. Hoidon kannalta haasteellinen alatyyppi on rintasyöpä, jossa ei ilmenny hormonihoidon ja täsmähoidon kohdemolekyylejä (kolmoisnegatiivinen rintasyöpä). Projektissa tutkitaan ilmentävätkö kolmoisnegatiiviset rintasyövät solun tukirankaa muokkaavia formiiniproteiineja. Tulosten perusteella selvitetään myös formiinien ilmentymisen vaikutus taudin ennusteeseen. Solukokeissa on osoitettu, että formiinien toimintaa voidaan lääkkeellisesti estää. Formiinit saattavat tulevaisuudessa toimia lääkehoidon kohteena.
Sirpa Jalkanen, Turun Yliopisto
Tulehdussolujen määrä sekä yksittäisten tulehdussolujen ominaisuudet näyttäisivät olevan merkityksellisiä syövän käyttäytymiselle. Clever-1 on proteiini, jota mm. immunosuppressiiviset makrofaagit ilmentävät. Clever-1 itsessään näyttäisi myös olevan immunosuppressiivinen molekyyli ja siten mahdollisesti sopiva syöpähoidon kohde. Tutkimuksen tarkoituksena on selvittää Clever-1 molekyylin esiintymistä eri syöpätyypeissä päämääränä sopivan syöpätyypin valinta kliinisiin kokeisiin.
Johanna Arola, Helsinki Biobank
Tiina Vesterinen, Institute for Molecular Medicine in Finland (FIMM)
Pulmonary carsinoid tumors cover 1-2% of all pulmonary malignancies. Accurate and timely diagnosis is required for successful treatment and improved prognosis. The aim of the study is to discover new or validate already existing diagnostic, predictive and/or prognostic markers for pulmonary carcinoids using retrospective material collected over decades in Finland.
Medaffcon Oy and Abbvie
Chronic lymphocytic leukemia is the most common leukemia in the Western world. The prognosis of the disease has become better irrespective of the disease stage, because of the resent developments of the treatment options. By creating a baseline description of the current CLL patient population and their common characteristics, this study helps to understand the basis of the disease as it is now, and estimate the treatment outcomes and also evaluate future treatment regimens compared to the current status. In addition, the study aim is to help defining the future resources needed to adequately treat each patient.
Päivi Lähteenmäki, Turku University Hospital
It has been suggested that survivors of pediatric cancer are significantly more likely than their siblings to suffer from cardiac complications. Aim of the study is to reveal genes that expose patients, who have received cancer treatment, to cardiac complications by focusing on long-term treatment-related effects. Information can be used for patients’ follow-up and also possibly for preventing adverse outcomes and for detecting cardiac risk factors in the early stages.
Klaus Elenius and Anna Knittle, University of Turku, Medical biochemistry and genetics
Lung cancer is the most common cancer in the world. The study aims to investigate ERBB4-mutations in non-small cell lung cancer (NSCLC) and evaluate the their clinical significance. This information can be utilized when improving medication and treatment of NSCLC.
Pirkko Härkönen, University of Turku, Department of Cell Biology and Anatomy
Estetrol (E4) is a natural estrogen produced by the human fetal liver during pregnancy and it is suggested as a promising new compound for menopausal hormone therapy and contraception. The study aims to study effects of estetrol (E4) in comparison to estradiol (E2) in an ex vivo model using explant cultures of normal breast and breast cancer samples.
The incidence of hepatocellular carcinoma, the etiology of the disease, medical practices, health care resource use, treatment costs and prognosis of the disease will be studied in a 13-year period in the Hospital District of Southwest Finland area. This information can be utilized when developing new treatment practices.
Emmy Verschuren, Institute for Molecular Medicine in Finland (FIMM)
The purpose of the study is to investigate the histotype-specific immune microenvironment of lung cancer. To this end, we will immunostain squamous cell carcinoma, adenosquamous carcinoma, and papillary adenocarcinoma to detect positively impacting neutrophils and negatively impacting T-cells. This work may lead to development of new histotype-specific therapies.
Kim Pettersson and Henna Kekki, Biotechnology, University of Turku
Tumor markers can be used to measure treatment efficacy and, in some cases, to monitor possible recurrence of the disease. Most of the tumor markers include sugar structures which change when cancer progresses, and these can be detected already at an early stage of the disease. The purpose of the study is to improve the specificity of the existing tumor markers and also to improve early diagnostics of cancer. We have developed diagnostic assays which recognize the sugar structures typical for cancer. The new sensitive assays would assist in the evaluation of patients' treatment response and likely enable detection of disease recurrency earlier than at present.
The purpose of this study is to determine the incidence and prevalence of biological subtypes of breast cancer at the time of diagnosis. Medical treatment practices are analyzed with regard to HER2-positive breast cancer cases. New HER2 immunotherapy drugs have improved the prognosis of patients with metastatic HER2-positive breast cancer significantly. In spite of this, there are great challenges associated with these subtypes of breast cancer due to their aggressiveness. The study aims to investigate the introduction of targeted drugs, and their impact on the incidence of metastatic cases in Finland.
Maria Gardberg, Turku University Hospital, Pathology
Glioblastoma is the most common malignant brain tumor. Glioblastoma cells are often found far away from the actual tumor. These tumor cells that exist outside of the tumor are problematic in terms of treatment, as they will cause relapse after treatment. Our research team studies processes by which glioblastoma cells invade surrounding tissue. We investigate cytoskeletal proteins that enhance cell movement, and search for ways to prevent their operation. In the long term, we aim to find targets proteins for targeted drug therapy.
Medaffcon Oy and AstraZeneca
Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation. In patients with severe asthma, some phenotype-guided treatments are already available however, further information is still needed on biochemical and biological markers that can be used both in diagnostics and in follow-up and which are predictive for the prognosis of different phenotypes and endotypes in asthma. The aim of the study is to investigate the prevalence of eosinophilic asthma among asthma patients in Finland and to describe patient characteristics of patients with eosinophilic asthma.
Bayer Pharma AG, Germany
Tumor samples of malignant melanomas, non-small cell lung cancer or other solid tumor indications will be analyzed for their mutations, gene expression, immunohistochemical markers etc. with a focus on immune-oncology. Furthermore, plasma samples shall be characterized for mutations in circulating tumor DNA/RNA in comparison to normal cell DNA in blood as well as for the levels of soluble proteins. This analysis will be correlated to clinical data and could help to advance the field of immune-oncology by e.g. identifying new targets, or biomarkers to predict progress.
The study aims at collecting real world data on patients with adenocarcinoma of NSCLC. The target is to search for clinical biomarkers that would support treatment selection. With the newly approved targeted therapies such as immunotherapies it will be important to have tools for selection of patients that would benefit of the treatment.
Bayer Pharma AG, Germany
Molecular research conducted on samples of a biobank could and should lead to clinical trials of novel therapeutics under development. To organize such clinical trials efficiently, it is relevant to know how many patients could be enrolled in a given site and how this number is affected by changes in the clinical trial protocol’s inclusion and exclusion criteria. In this study, a series of clinical trials across several indications are simulated in the database of Auria biobank to study these effects and thus to optimize the future clinical trial protocol.
Bayer Pharma AG, Germany
Vasopressin hormones are a family of peptides released from the hypothalamus derived from a common pre pro form. We aim to identify longitudinal reference levels in a large cohort of CKD patients to correlate with disease stage. Also, such data from heart failure patients will be assessed. We plan to evaluate e. g. effects of circadian rhythm, comorbidities and respective treatments, demographics and life style on hormone levels. A definition of cut-off levels could help to identify patients at risk for worsening conditions (such as loss of kidney function in CKD) or to predict progression or outcome of treatment.
Elina Uusitalo and Juha Peltonen, Department of Biomedicine, University of Turku
The incidence of breast cancer is higher in patients with neurofibromatosis type 1 (NF1) than in the general Finnish population. The prognosis of breast cancer in NF1 patients is also worse. The aim of the study is to investigate how NF1 breast cancers differ from breast cancers in patients who do not have NF1.